VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

NCT02996461 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

NIH

Sponsor class

Conditions

Prevention of Zika Infection
Zika-Specific Immune Response

Interventions

BIOLOGICAL: VRC-ZKADNA090-00-VP

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)